Last reviewed · How we verify
A Study of Anti-Lewis Y Chimeric Antigen Receptor-T Cells (LeY-CAR-T) in Patients With Solid Tumours
This clinical trial is an open-label, single-centre, phase I study designed to investigate the safety and tolerability of a single infusion of autologous peripheral blood T-lymphocytes transduced with the anti-LeY-scFv-CD28-ζ vector (LeY CAR T-cells) The primary aim of the trial is to evaluate the safety and tolerability of LeY CAR T cells in patients with Lewis Y antigen-expressing, advanced solid tumours. The secondary aim of the trial is to assess the anti-tumour activity of LeY CAR T cells in patients with LeY antigen-expressing, advanced solid tumours. Patients aged 18 years or older with advanced solid tumours have consented to pre-screening that allows their tumours to be assessed for LeY expression by immunohistochemistry. Patients whose tumours test positive for LeY were then able to proceed to eligibility screening and, if found to fulfil the eligibility criteria, were registered in the study. The study involves an initial dose escalation phase followed by an expansion phase.
Details
| Lead sponsor | Peter MacCallum Cancer Centre, Australia |
|---|---|
| Phase | PHASE1 |
| Status | COMPLETED |
| Enrolment | 20 |
| Start date | Thu Nov 24 2016 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Fri Apr 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Advanced Cancer
Interventions
- LeY CAR T cells
Countries
Australia